Background: Familial hemiplegic migraine type 1 (FHM1) is a form of migraine with aura caused by heterozygous mutations in 4 genes: CACNA1A, ATP1A2, SNC1A and PRRT2, but further heterogeneity is expected. Here have been described clinical and molecular features in patients suffering from migraine with Aura (MA), without (MO) and hemiplegic migraine attacks. Next Generation Sequencing by TruSeq Custom Amplicon for CACNA1A and ATP1A2 gene has been performed. All genetic variants have been confirmed by Sanger sequencing and all samples were also analyzed with MLPA assay for ATP1A2-CACNA1A genes to detect duplication or deletion. All MLPA data were verified by Real Time PCR. Results: Sequencing analysis showed 3 point mutations, two novel variants and one already described in literature. Moreover, MLPA analysis showed 3 deletions in 9 sporadic hemiplegic migraine (18%), in 3 patients with non-hemiplegic migraine (4.1%) and in 3 patients affected by episodic ataxia (20%). Two sporadic patients showed a deletion in exons 41-43, while the rest of HM patients (5) showed a deletion in the terminal part of the CACNA1A gene. About episodic ataxia, we have identified deletions in exon 12-15 and in exon 47. Finally, in migraine patients, we have found different subjects affected by different phenotypes deleted in exon 47.
Background
CACNA1A gene encodes the α1 subunit of neuronal Ca V 2.1 (P/Q-type) voltage-gated calcium channels that are widely expressed throughout the central nervous system (CNS). Mutations in the CACNA1A gene have been found to be responsible for three disorders with autosomal dominant inheritance: i) Episodic Ataxia 2 (EA2; MIM: 108500), ii) familial hemiplegic migraine type 1 (FHM1; MIM: 141500), and iii) spinocerebellar ataxia type 6 (SCA6; MIM: 183086). Clinical overlap between the three disorders in terms of symptoms has been previously reported [1] [2] [3] . Interesting, Pradotto and collaborators [4] , described, for the first time, a common mutation in CACNA1A gene in different phenotypes, such as EA2 and SCA6, opening a new prospective about the association between distinct phenotypes caused by the same CACNA1A mutation.
About FHM1, more than 20 missense mutations are known to be associated with a broad spectrum of clinical features besides hemiplegic migraine [5] . Mutations in CACNA1A gene explain around 30-50% of the FHM cases [5] , in fact, other genes as ATP1A2, SCN1A, PRRT2 have been associate to FHM1 disease [5] [6] [7] .
So far, there is no evidence for works investigating deletions or duplication in CACNA1A in patients FHM1 while in EA2 patients, different deletions [8] [9] [10] in CAC-NA1A gene have been found to lead to loss-of-function of recombinant human CaV2.1 channels. About the last CACNA1A associated disorder, SCA6 disease, CAC-NA1A caused the pathology by the expansion of CAG repeat in the α1A subunit of the voltage-dependent calcium channel gene [11] .
Moreover, a relevant number of EA2 and FHM cases remain genetically undiagnosed, it can be imputed to incomplete sequencing analysis of the CACNA1A gene, to genetic heterogeneity [12] [13] [14] [15] or to the occurrence of CNVs undetectable by exon sequencing. Indeed, in recent years, quantitative analyses as MLPA or QMPSF allowed to identify large genomic deletions involving the CACNA1A gene and associate to EA2 and different CACNA1A related phenotypes.
This work would emphasize the importance of the genetic rearrangement of CACNA1A gene in different phenotype and also to highlight the importance of using multiple techniques, in order to reach a higher diagnostic sensitivity and specificity.
Herein, we present an important screening of CAC-NA1A gene to identify new point mutations (by Next Generation Sequencing) and to search CNVs (using MLPA assay) in patients affected by hemiplegic migraine, episodic ataxia and, for the first time, in migraine with aura not hemiplegic (MA) and migraine without aura (MO). To perform a complete analysis of CAC-NA1A gene, we have also investigated the expansion of the CAG repeat in the α1A subunit of CACNA1A associated to SCA6 phenotype.
Methods

Patients and controls
The clinical diagnosis followed the IHS 2nd edition criteria having collected a written informed consent to genetic tests at "C. Mondino" Neurological Institute in Pavia and at the University-Hospital S. Anna in Ferrara.
We collected peripheral blood samples of 50 patients with hemiplegic migraine (36 sporadic and 14 familial cases), of 15 patients with Episodic Ataxia2 (EA2) and of 72 patients with MA or MO. Moreover we enrolled 70 healthy volunteers age 65 years or more after obtaining written informed consent (Table 1) .
Sequencing analysis
We purified genomic DNA from blood by automatic extraction (Maxwell® 16 Blood DNA -Promega). Next Generation Sequencing by TruSeq Custom Amplicon for CACNA1A, ATP1A2 SCN1A, PRRT2 genes has been performed (Illumina) according to the manufacturers' instructions. DNA analysis has been carried out using Illumina MySeq. All genetic variants have been confirmed by Sanger sequencing, PCR-amplified the 47 exons and 80 base pairs of the flanking intronic sequences of CACNA1A (NC_000019.9). All patients have been also screened for ATP1A2, SCN1A, PRRT2 mutations.
MLPA and real time PCR
Search of multi exon rearrangements was performed by MLPA assay using the P348-A2 ATP1A2-CACNA1A probe mix (SALSA MLPA Kit, MRC-Holland). Identification of deletion/duplications was confirmed by quantitative real -time PCR (qPCR). PCR reactions were carried out using a Biorad IQ5 (BioRad) in a 96-well optical plate with a final reaction volume of 50 μl. About 10 ng of DNA were subjected to thermal cycling conditions with a pre-run of 2 min at 50°C and 10 min at 95°C. Cycle conditions were 40 cycles at 95°C for 15 s and 60°C for 1 min according to the Sybr Green Real Time PCR Protocol (primers are available upon request). Analysis of relative gene expression data have been performed using real-time quantitative PCR and the 2-ΔΔCT method [16] , the starting copy number of the unknown samples was determined in comparison with the known copy number of the calibrator sample, using the 2-(ΔΔCt) method. As a reference gene, we used GAPDH. P Values in patients were compared to results obtained in 70 normal individuals, deemed free of neurological disorders. All the experiments have been performed in triplicates.
Microsatellite STR analysis
All patients and healthy controls have been genotyped for the (CAG)n microsatellite markers. Accordingly to the already published method [17] , all samples have been run by sequencer DNA analyser ABI 3031 (microsatellite analysis) and analysed by the Gene Mapper software.
Results
Sequencing analysis
Genetic analysis of the CACNA1A gene with direct sequencing, in a cohort of migraine sufferers (HM and MA/MO) identified 3 different point mutations (Table 2 ; Fig. 1a) .
The first patient affected by FHM showed the missense mutation E1015K, already described in literature [18] as pathogenetic.
Next, we have identified two new mutations, not reported in literature or in disease databases. The first one is the missense variation Arg2157Gly (R2157G) that we found in a Moroccan hemiplegic migraine patient; unfortunately no relatives are available for segregation analysis (Fig. 1b) . In silico analysis with Polyphen software (http://genetics.bwh.harvard.edu/pph2/) predicted the R2157G mutation as probably damaging with a score of 0.998. The pathogenity has been confirmed also by SIFT This variation has an amino acidic substitution corresponding to an Isoleucine into a Threonine, (I1512T) two essential amino acids that have a chiral side chain.
In silico analysis with Polyphen software predicted the I1512T mutation as probably damaging with a score of 0.999. These predictions were confirmed using Predict Protein (https://www.predictprotein.org).
MLPA results
The samples analysed showed the presence of an intragenic deletion in 9 subjects with sporadic hemiplegic migraine (18%), in 3 patients with non-hemiplegic migraine (4.1%) and in 3 patients affected by episodic ataxia (20%) ( Table 3) . Sporadic hemiplegic migraine: two patients showed a deletion in exons 41-43, while the rest of HM patients [5] showed a deletion in the terminal part of the CAC-NA1A gene (ex 47).
Episodic ataxia: in a female EA patient (and her affected son) we identified a deletion in exon 12-15, while a second patient showed a deletion in exon 47.
Migraine: the three deleted patients showed the same deletion in exon 47, but two different phenotypes, as MA [1] and MO [2] .
Also in one healthy control we have detected a deletion in exon 47.
Microsatellites
Expansion of the CAG repeat in the α1A subunit of the voltage-dependent calcium channel gene CACNA1A, leads to the Spinocerebellar ataxia type 6 (SCA6, MIM 183086). This is a late-onset, slowly progressive neurodegenerative disorder accounting for between 6 and 32% of families with autosomal dominant ataxia [11] . None of the patients had expanded CAG repeats in the 3'-UTR of CACNA1A.
Discussion
Here we report an exhaustive screening of the CACNA1A gene in a large sample of 137 patients with four clinical phenotypes: FHM1, sporadic HM, EA2, MA and MO. The study was addressed through Next Generation Sequencing and MLPA analyses in the patients.
In the last years an increasing number of point mutations in CACNA1A have been reported as causative of FHM-1 and EA2 [19, 20] .
In our cohort of patients, Sanger analysis identified only three point mutations in the CACNA1A gene; the E1015K, previously described associated with different migraine phenotypes [18] , was identified in a patient with a clinical diagnosis of Hemiplegic migraine without family history.
Two novels variations (I1521T, R2157G) have been detected in three unrelated patients with FHM and in silico studies predicted both the variations as damaging.
Patients with EA2 and MA/MO phenotypes resulted negative to sequencing analysis, suggesting that other genes, known to be causative of FHM such as ATP1A2, SNC1A and PRRT2, could be involved and are worth to be screened. Our results expand the number of small mutations of CACNA1A gene associated with HM/FHM phenotype but on the other hand highlight the need to carry out a second level analysis to search for gross genomic rearrangement.
Therefore, in our cohort of patients negative to Sanger sequencing, we performed MLPA analysis of CACNA1A gene and we found different deletions in the C-terminus region of the gene. To date, deletions in the CACNA1A gene have been reported in literature but associated exclusively to an EA2 phenotype.
Riant and collaborators [8] described a deletion spanning from exon 38 to 40 and removing 105 amino acids in the proximal half of the cytoplasmatic C-terminal tail of the protein, that is essential for channel function. This result has been reported also by others [9, 10] .
We identified a novel deletion of exons 12-15 in a female patient with EA2 and in her son affected by congenital night blindness. The deletion of 12-15 exons is out of frame and predicts to cause premature truncation of the CACNA1A protein product; or its complete absence via mRNA decay.
The novelty of this report is the intrafamilial phenotypic variability associated to the same deletion, giving rise to a classical EA2 in the mother and to a more complex phenotype in the son.
A part from this family, in patients with migraine (HM, MA and MO), we have detected different deletions in the 3′ end of CACNA1A (Fig. 2) .
Deletions of more than one exon were present only in patients with sporadic HM, instead the single exon 47 deletion was found associated to different clinical presentations: HM (four cases), EA2 (one case), MO (two cases) and MA (one case).
The high frequency of exon 47 deletion in our cohort lead us to speculate if it might be a polymorphism or a mutational hot spot, harbouring also the triplet repeat involved in the pathogenesis of SCA6.
We have detected the single exon 47 deletion in one subject of the controls cohort and in this subject, clinical investigation was negative for neurological involvement and he did not refer migraine; we cannot exclude a low penetrance of the deletion in this patient or that he will manifest clinical signs in the years to come.Further investigation and functional studies are necessary to better understand the role of CACNA1A exon 47 deletion in migraine disorders.
Our findings expand the spectrum of clinical phenotype associated with deletions in the 3′ end of CACNA1A gene. Interestingly, all our deleted patients manifested early motor and headache symptoms in the juvenile period or even in preteen years. If this correlate to the specific function of the gene product during development is unclear, although mutations in other FHM genes (ATP1A2 and SCN1A) may occur frequently in episodic ictal brain dysfunctions in childhood. The other reports of deletions in CACNA1A gene are in keeping with these findings, suggesting that deletions in the gene are associated with an onset of clinical manifestations before the age of 30 [8, 9] .
Conclusions
In conclusion, the four clinical phenotypes we have included in this study (FHM1, sporadic HM, EA2, MA and MO) should be considered part of the same disease spectrum and for this group of diseases it should be kept in mind the genetic and allelic heterogeneity and also the intrafamilial / interfamilial clinical variability.
Moreover, in patients with migraine phenotypes and episodic ataxia is becoming mandatory the screening of gross rearrangements of CACNA1A gene for a complete genetic workup. 
